Faron Pharmaceuticals Oy (FPHAF)
Faron Pharmaceuticals Oy operates in the Biotechnology industry of the Healthcare sector, headquartered in Turku, FI. The stock last traded at $3.30, up 0.00% on the session, giving a market capitalisation of $209.5M. On trailing twelve-month figures it carries a trailing P/E of -2.96, a net margin of 0.0%. Its beta of 0.18 implies it has historically moved less than the broad market.
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical firm dedicated to drug discovery and development. The company is advancing a pipeline of proprietary drug candidates that harness immune modulation to address significant unmet medical needs, spanning immuno-oncology, organ protection, and regenerative medicine. Its principal product candidates include Traumakine, an intravenous interferon beta-1a therapy, which targets acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant procedures, and ischemia-reperfusion injury. Additionally, Bexmarilimab stands as a significant candidate, representing a novel precision immunotherapy for various cancers, such as solid tumors, non-small cell lung carcinoma, and hematological malignancies. Faron also has Haematokine in development, a new chemical entity and AOC3 inhibitor designed to treat hematological malignancies and bone marrow conditions. Established in 2003, Faron Pharmaceuticals Oy maintains its headquarters in Turku, Finland.
Faron Pharmaceuticals Oy is most often compared with the following Healthcare names: